Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06717438 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])

StatusActive, Not Recruiting
PhasePhase 2
SponsorShionogi
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified
    • Primary and study completion moved earlier from Jan 31, 2030 to Dec 31, 2027
    v6
  2. Trial status: Enrolling by Invitation to Active, Not Recruitingv5
  3. Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Start date changed from estimate of Mar 1, 2027 to May 13, 2025
    v4
  4. Primary completion date: Mar 17, 2026 to Jan 31, 2030
    • Start date: Jan 31, 2025 to Mar 1, 2027
    • Study completion date: Sep 15, 2026 to Jan 31, 2030
    v3
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Shionogi
45 trials monitored
See 2 trials at risk
The primary objective of this study is to assess the efficacy, safety, and tolerability of BPN14770 in participants aged 9 to 45 years with JS.
Trial Details
NCT Number NCT06717438
Lead Sponsor Shionogi
Conditions
(from sponsor)		 Jordan's Syndrome, PPP2R5D Neurodevelopmental Disorder
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov